Projects per year
Personal profile
Personal profile
While completing her postdoctoral training, Dr. Greene studied under the renowned Dr. Stanley Appel, the former chair of the Department of Neurology at Houston Methodist Hospital and the founder of the Houston Methodist Neurological Institute. After completion of a fellowship in Dr. Appel’s laboratory, she became a tenure track Associate Professor of Neurology at the Baylor College of Medicine in Houston, Texas. Dr. Greene is a member of the American Academy of Neurology, the American Board of Psychiatry and Neurology, and a recipient of the Robert Wood Johnson Foundation’s Minority Medical Faculty Development Program. She joined the Houston Methodist Specialty Physician Group in 2005.
Research interests
Dr. Greene's research aims to characterize the peripheral immune inflammatory response in ALS and other neurodegenerative diseases, and identify the potential markers that may reflect disease activity and progression. Her translational research seeks to identify and develop effective therapies that positively alter the natural progression of these diseases, including Myotonic Dystrophy, myasthenia gravis, and chronic inflammatory polyneuropathies.
Education/Academic qualification
Research Fellowship, Baylor College of Medicine
Jul 1 1999 → Jun 30 2002
Award Date: Jun 30 2002
Neurology, Residency, Baylor College of Medicine
Jul 1 1996 → Jun 30 1999
Award Date: Jun 30 1999
Internal Medicine, Internship, Baylor College of Medicine
Jun 24 1995 → Jun 23 1996
Award Date: Jun 23 1996
MD, University of Texas at Houston Medical School
Jun 15 1992 → Jun 30 1995
Award Date: Jun 2 1995
Research Area Keywords
- Neurosciences
- Regenerative Medicine
Free-text keywords
- Neurology
- ALS
- Biomarkers
- Dendritic cells
- MCP-1
- Microglia
- Stem cells
Fingerprint
- 1 Similar Profiles
Collaborations and top research areas from the last five years
-
A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects with Non-Oncology Plasma Cell-Related Diseases
Liao, B. (PI), Ganguly, S. (Key Personnel), Greene, E. P. (Key Personnel) & Shroff, S. (Key Personnel)
5/12/25 → …
Project: Clinical Trial
-
An open-label, multi-center, phase I/II study to assess safety, efficacy, and cellular kinetics of YTB323 in participants with treatment-resistant generalized myasthenia gravis.
Greene, E. P. (PI), Liao, B. (Key Personnel) & Shroff, S. (Key Personnel)
5/8/25 → …
Project: Clinical Trial
-
Home Visits are the Answer for Homebound Patients with Amyotrophic Lateral Sclerosis
Greene, E. P. (PI) & Liao, B. (Key Personnel)
5/9/24 → …
Project: Clinical Trial
-
Collaborative Remote Physical Examination: Transforming Medical and Nursing Practice
Greene, E. P. (PI)
9/1/23 → 8/31/26
Project: Federal Funding Agencies
-
HEALEY ALS Platform Trial - Regimen-Specific Appendix D - For pridopidine 45 mg oral capsule administered twice daily (BID) or its matching placebo.
Appel, S. H. (PI), Shroff, S. (PI), Greene, E. P. (CoI) & Liao, B. (CoI)
6/29/21 → 7/23/25
Project: Non Profit
-
Rare variant analyses validate known ALS genes in a multi-ethnic population and identifies ANTXR2 as a candidate in PLS
The New York Genome Center ALS Sequencing Consortium, Scottish Genomes Partnership, ALS COSMOS Study Group, PLS COSMOS Study Group & GTAC Investigators, Dec 2024, In: BMC genomics. 25, 1, 651.Research output: Contribution to journal › Article › peer-review
-
Antisense oligonucleotide targeting DMPK in patients with myotonic dystrophy type 1: a multicentre, randomised, dose-escalation, placebo-controlled, phase 1/2a trial
Thornton, C. A., Moxley, R. T., Eichinger, K., Heatwole, C., Mignon, L., Arnold, W. D., Ashizawa, T., Day, J. W., Dent, G., Tanner, M. K., Duong, T., Greene, E. P., Herbelin, L., Johnson, N. E., King, W., Kissel, J. T., Leung, D. G., Lott, D. J., Norris, D. A. & Pucillo, E. M. & 7 others, , Mar 2023, In: The Lancet Neurology. 22, 3, p. 218-228 11 p.Research output: Contribution to journal › Article › peer-review
25 Scopus citations -
Adaptive Platform Trials to Transform Amyotrophic Lateral Sclerosis Therapy Development
for the Healey ALS Platform Trial Study Group, HEALEY ALS Platform Trial Study Group, Biostatisticians, Investigators, Clinical Operations Team & Medical Monitors, Feb 1 2022, In: Annals of Neurology. 91, 2, p. 165-175 11 p.Research output: Contribution to journal › Article › peer-review
64 Scopus citations -
Decisions With Patients and Families Regarding Aducanumab in Alzheimer Disease, With Recommendations for Consent: AAN Position Statement
the Ethics, Law, and Humanities Committee (a joint committee of the AAN, ANA, and CNS), Jan 25 2022, In: Neurology. 98, 4, p. 154-159 6 p.Research output: Contribution to journal › Article › peer-review
Open Access19 Scopus citations -
Contemporary Neuroscience Core Curriculum for Medical Schools
The AAN Undergraduate Education Subcommittee (UES) & The AAN Education Committee, Oct 5 2021, In: Neurology. 97, 14, p. 675-684 10 p.Research output: Contribution to journal › Article › peer-review
Open Access4 Scopus citations